NasdaqGS:TSHABiotechs
Is Taysha (TSHA) Balancing TSHA-102 Trial Progress and New Equity Shelf in a Sustainable Way?
Taysha Gene Therapies has reported past progress in its TSHA-102 Rett syndrome program, including dosing the first patient in the REVEAL pivotal trial and advancing enrollment, alongside further FDA alignment on the ASPIRE safety-focused study and its planned BLA submission for a broad patient population.
In parallel, Taysha filed an approximately US$87.91 million shelf registration for nearly 17,976,582 common shares tied to an ESOP-related offering, highlighting ongoing preparations to...